Enanta Pharmaceuticals, Inc. (ENTA): Price and Financial Metrics


Enanta Pharmaceuticals, Inc. (ENTA)

Today's Latest Price: $43.67 USD

0.10 (0.23%)

Updated Nov 23 4:00pm

Add ENTA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

ENTA Stock Summary

  • ENTA's current price/earnings ratio is 369.94, which is higher than 97.72% of US stocks with positive earnings.
  • Of note is the ratio of Enanta Pharmaceuticals Inc's sales and general administrative expense to its total operating expenses; just 8.04% of US stocks have a lower such ratio.
  • The volatility of Enanta Pharmaceuticals Inc's share price is greater than that of just 3.16% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Enanta Pharmaceuticals Inc are SLAB, STRO, TNAV, EXEL, and SRDX.
  • Visit ENTA's SEC page to see the company's official filings. To visit the company's web site, go to www.enanta.com.

ENTA Stock Price Chart Interactive Chart >

Price chart for ENTA

ENTA Price/Volume Stats

Current price $43.67 52-week high $67.88
Prev. close $43.57 52-week low $38.40
Day low $43.24 Volume 112,872
Day high $45.14 Avg. volume 188,011
50-day MA $45.02 Dividend yield N/A
200-day MA $49.18 Market Cap 876.54M

Enanta Pharmaceuticals, Inc. (ENTA) Company Bio


Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses a chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. The company was founded in 1995 and is based in Watertown, Massachusetts.

ENTA Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$43.67$16.81 -61%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Enanta Pharmaceuticals Inc. To summarize, we found that Enanta Pharmaceuticals Inc ranked in the 26th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Enanta Pharmaceuticals Inc ended up being:

  • The business' balance sheet suggests that 1% of the company's capital is sourced from debt; this is greater than merely 5.97% of the free cash flow producing stocks we're observing.
  • As a business, Enanta Pharmaceuticals Inc experienced a tax rate of about 33% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than 91.02% of stocks generating free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-62%
1%-62%
2%-61%
3%-61%
4%-61%
5%-60%

Want more companies with a valuation profile/forecast similar to that of Enanta Pharmaceuticals Inc? See ICUI, WAT, ILMN, XRAY, and A.


ENTA Latest News Stream


Event/Time News Detail
Loading, please wait...

ENTA Latest Social Stream


Loading social stream, please wait...

View Full ENTA Social Stream

Latest ENTA News From Around the Web

Below are the latest news stories about Enanta Pharmaceuticals Inc that investors may wish to consider to help them evaluate ENTA as an investment opportunity.

Enanta Pharmaceuticals to Present at the 4th Annual H.C. Wainwright Virtual NASH Investor Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present at the 4th Annual H.C. Wainwright Virtual NASH Investor Conference

Business Wire | September 28, 2020

Axsome Reports Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma

Axsome reports positive data from Major Depressive Disorder study Axsome Therapeutics Inc. (AXSM) announced encouraging results from its GEMINI Phase 3 trial. It was a randomized, double-blind, placebo-controlled, multi-center, U.S. trial, and involved 327 adult patients with confirmed moderate to severe MDD. The data showed that AXS-05 was showed rapid...

Avisol Capital Partners on Seeking Alpha | September 21, 2020

Enanta initiates early-stage NASH study with EDP-297

Enanta Pharmaceuticals ([[ENTA]] +2.0%) has dosed the first patient in its Phase 1 trial of EDP-297, potent and targeted follow-on farnesoid X receptor agonist, for the treatment of non-alcoholic steatohepatitis ((NASH)).“In preclinical studies, EDP-297 demonstrated a compelling product profile, with a potency greater than that published on any FXR agonist in clinical...

Seeking Alpha | September 14, 2020

Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-297, its Highly Potent and Targeted Follow-On Farnesoid X Receptor Agonist for the Treatment of Non-Alcoholic Steatohepatitis

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-297, its Highly Potent and Targeted Follow-On Farnesoid X Receptor Agonist for NASH

Business Wire | September 14, 2020

Enanta Pharmaceuticals to Participate in Upcoming September Conferences

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Participate in Upcoming September Conferences

Business Wire | September 3, 2020

Read More 'ENTA' Stories Here

ENTA Price Returns

1-mo -0.41%
3-mo -13.76%
6-mo -13.88%
1-year -28.10%
3-year -8.75%
5-year 36.47%
YTD -29.31%
2019 -12.78%
2018 20.71%
2017 75.16%
2016 1.45%
2015 -35.06%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.1358 seconds.